Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review

Abstract

Sharon Cowley, Geraldine McCarthy Department of Rheumatology, Mater Misericordiae University Hospital, Dublin, IrelandCorrespondence: Sharon Cowley, Mater Misericordiae University Hospital, Dublin, Ireland, Email [email protected]: Calcium Pyrophosphate Dihydrate (CPPD) crystal-related arthropathies are a common cause of acute and chronic arthritis caused by the deposition of calcium pyrophosphate crystals in joints and soft tissues, resulting in inflammation and joint damage. They present with a wide spectrum of clinical manifestations and often present challenges to diagnosis and management as they commonly affect older co-morbid patients. The challenges are compounded by a lack of a well-defined description of CPPD. However, an international expert-driven process is underway to develop CPPD classification criteria. Treatment is also problematic as unlike gout, there are no agents available that decrease the crystal burden. Treatment options have often been extrapolated from gout treatment pathways without having extensive trials or a solid evidence base. It is hoped the new CPPD classification guidelines will contribute to large multicentre studies, with well-defined patient cohorts, which will facilitate the production of high-quality evidence to guide the management of this condition. Here, we discuss the barriers and facilitators in diagnosing and treating CPPD-related arthropathy.Keywords: crystal arthropathy, calcium pyrophosphate dihydrate, CPPD

Keywords

• crystal arthropathy
• calcium pyrophosphate dihydrate
• cppd